Literature DB >> 865343

Content analysis of drug-detailing by pharmaceutical representatives.

E Hemminki.   

Abstract

Drug detailing is important in drug prescribing. This report describes a study made on drug presentations to groups of doctors in Helsinki. The method was silent observation of presentations given by medical representatives. Analysis of the content of the presentations revealed that side-effects and contraindications were often neglected; the drug presented was always recommended as the drug of choice; other forms of treatment were seldom mentioned. References to Finnish doctors doing clinical trials with the drugs were often made. Even though this study was restricted, its results show that drug detailing and its significance in post-graduate education call for more attention.

Mesh:

Substances:

Year:  1977        PMID: 865343     DOI: 10.1111/j.1365-2923.1977.tb00595.x

Source DB:  PubMed          Journal:  Med Educ        ISSN: 0308-0110            Impact factor:   6.251


  12 in total

1.  The pharmaceutical industry.

Authors: 
Journal:  Occas Pap R Coll Gen Pract       Date:  1991-11

2.  Introducing a new drug: an objection.

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  1988-05       Impact factor: 3.275

Review 3.  What information do physicians receive from pharmaceutical representatives?

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  1997-05       Impact factor: 3.275

4.  Limitations on quality assurance effectiveness: Improving psychiatric inpatient drug prescribing habits of physicians.

Authors:  S R Eastaugh
Journal:  J Med Syst       Date:  1980       Impact factor: 4.460

5.  Attitudes of general practitioners in New Zealand to pharmaceutical representatives.

Authors:  A N Thomson; B J Craig; P M Barham
Journal:  Br J Gen Pract       Date:  1994-05       Impact factor: 5.386

6.  Drug promotion and the doctor.

Authors:  K O'Malley; M O'Hanrahan
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 7.  Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.

Authors:  Geoffrey K Spurling; Peter R Mansfield; Brett D Montgomery; Joel Lexchin; Jenny Doust; Noordin Othman; Agnes I Vitry
Journal:  PLoS Med       Date:  2010-10-19       Impact factor: 11.069

8.  Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia.

Authors:  Noordin Othman; Agnes I Vitry; Elizabeth E Roughead; Shaiful B Ismail; Khairani Omar
Journal:  BMC Public Health       Date:  2010-11-30       Impact factor: 3.295

9.  Doctors' opinions of information provided by Libyan pharmaceutical company representatives.

Authors:  Mustafa A Alssageer; Stefan R Kowalski
Journal:  Libyan J Med       Date:  2012-11-28       Impact factor: 1.657

10.  Characteristics and impact of drug detailing for gabapentin.

Authors:  Michael A Steinman; G Michael Harper; Mary-Margaret Chren; C Seth Landefeld; Lisa A Bero
Journal:  PLoS Med       Date:  2007-04       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.